IFP Advisors
STOK icon

IFP Advisors’s Stoke Therapeutics STOK Stock Holding History

IFP Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$130 Hold
5
– – ﹤0.01% 4943
2026
Q2 		$164 Hold
5
– – ﹤0.01% 4890
2026
Q1 		$163 Hold
5
– – ﹤0.01% 4653
2025
Q4 		$159 Hold
5
– – ﹤0.01% 4513
2025
Q3 		$118 Buy
+5
New +$86 ﹤0.01% 4516
2025
Q2 		– Hold
0
– – – 4602
2025
Q1 		– Sell
-6
Closed -$66 – 4619
2024
Q4 		$66 Buy
+6
New +$74 ﹤0.01% 4169

Other funds holding STOK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
SYM Financial Corp
SYM Financial Corp Winona Lake, Indiana $1.31B AUM 18.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

IFP Advisors's STOK Position: Q3 2026 in Review

IFP Advisors held its Stoke Therapeutics (STOK) position steady in Q3 2026 at 5 shares worth $130. The position accounts for ﹤0.01% of the portfolio, ranked #4943.

IFP Advisors first reported a position in STOK in Q4 2024 and has held it in 6 quarters since. The position peaked at $164 in Q2 2026. 61 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • IFP Advisors held 5 shares of Stoke Therapeutics worth $130 as of Q3 2026.
  • IFP Advisors left its Stoke Therapeutics share count unchanged in Q3 2026.
  • Stoke Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #4943 holding.
  • IFP Advisors first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • IFP Advisors's Stoke Therapeutics position peaked at $164 in Q2 2026.
  • 61 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.